Unnati Pharmax

Oxitan Injection
Composition: Oxaliplatin Injection (50mg / 100mg)
International Trade Name: Eloxatin®

Oxitan is a high-quality Oxaliplatin Injection, a bioequivalent formulation of the internationally recognized platinum-based anticancer agent marketed under the brand name Eloxatin®. Manufactured in WHO-GMP certified facilities, Oxitan Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in colorectal and gastrointestinal cancers.

Oxaliplatin is a third-generation platinum compound that exerts cytotoxic activity by forming DNA cross-links, inhibiting DNA replication and transcription, and inducing apoptosis in rapidly dividing tumor cells. Oxitan Injection is primarily indicated for the treatment of colorectal cancer, including adjuvant therapy and metastatic settings, commonly administered in combination regimens such as FOLFOX.

Oxitan Injection is manufactured under stringent GMP and injectable quality standards to ensure consistent potency, safety, and stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Bleocel Injection
Composition: Bleomycin Injection IP
International Trade Name: Blenoxane®

Bleocel is a high-quality Bleomycin Injection, a bioequivalent formulation of the internationally recognized antineoplastic antibiotic marketed under the brand name Blenoxane®. Manufactured in WHO-GMP certified facilities, Bleocel Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, testicular cancer, and other solid tumors.

Bleomycin is a glycopeptide antibiotic with antitumor activity that induces DNA strand breaks, inhibiting DNA synthesis and causing cancer cell apoptosis. Bleocel Injection is primarily indicated for the treatment of Hodgkin’s and non-Hodgkin’s lymphomas, testicular carcinoma, ovarian carcinoma, and certain head & neck cancers, as part of combination chemotherapy regimens.

Bleocel Injection is manufactured under stringent GMP and injectable quality standards to ensure consistent potency, safety, and stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Oxyrea 100 Injection
Composition: Oxaliplatin Injection 100mg
International Trade Name: Eloxatin®

Oxyrea 100 is a high-quality Oxaliplatin 100mg Injection, a bioequivalent formulation of the internationally recognized platinum-based anticancer agent marketed under the brand name Eloxatin®. Manufactured in WHO-GMP certified facilities, Oxyrea Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gastrointestinal malignancies.

Oxaliplatin is a third-generation platinum compound that exerts cytotoxic activity by forming DNA cross-links, thereby inhibiting DNA replication and transcription, leading to cancer cell death. Oxyrea 100mg Injection is primarily indicated for the treatment of colorectal cancer, including adjuvant and metastatic settings, commonly used in combination regimens such as FOLFOX, as well as for other gastrointestinal cancers as per approved protocols.

Oxyrea 100mg Injection is manufactured under stringent GMP and injectable quality standards to ensure consistent potency, safety, and stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Oxyrea 50 Injection
Composition: Oxaliplatin Injection 50mg
International Trade Name: Eloxatin®

Oxyrea 50 is a high-quality Oxaliplatin 50mg Injection, a bioequivalent formulation of the internationally recognized platinum-based anticancer agent marketed under the brand name Eloxatin®. Manufactured in WHO-GMP certified facilities, Oxyrea Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gastrointestinal malignancies.

Oxaliplatin is a third-generation platinum compound that exerts cytotoxic activity by forming DNA cross-links, thereby inhibiting DNA replication and transcription, leading to cancer cell apoptosis. Oxyrea 50mg Injection is primarily indicated for the treatment of colorectal cancer, including adjuvant and metastatic settings, commonly used in combination regimens such as FOLFOX, as well as for other gastrointestinal cancers according to approved protocols.

Oxyrea 50mg Injection is manufactured under stringent GMP and injectable quality standards to ensure consistent potency, safety, and stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Oxalinamo 100mg Injection
Composition: Oxaliplatin Injection 100mg
International Trade Name: Eloxatin®

Oxalinamo 100 is a high-quality Oxaliplatin 100mg Injection, a bioequivalent formulation of the internationally recognized platinum-based anticancer agent marketed under the brand name Eloxatin®. Manufactured in WHO-GMP certified facilities, Oxalinamo Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in colorectal and gastrointestinal cancers.

Oxaliplatin is a third-generation platinum compound that exerts cytotoxic activity by forming DNA cross-links, inhibiting DNA replication and transcription, and inducing apoptosis in rapidly dividing tumor cells. Oxalinamo 100mg Injection is primarily indicated for the treatment of colorectal cancer, including adjuvant therapy and metastatic settings, commonly administered in combination regimens such as FOLFOX.

Oxalinamo 100mg Injection is manufactured under stringent GMP and injectable quality standards to ensure consistent potency, safety, and stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Oxaltero 100mg Injection
Composition: Oxaliplatin Injection 100mg
International Trade Name: Eloxatin®

Oxaltero 100 is a high-quality Oxaliplatin 100mg Injection, a bioequivalent formulation of the internationally recognized platinum-based anticancer agent marketed under the brand name Eloxatin®. Manufactured in WHO-GMP certified facilities, Oxaltero Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in colorectal and gastrointestinal cancers.

Oxaliplatin is a third-generation platinum compound that exerts cytotoxic activity by forming DNA cross-links, inhibiting DNA replication and transcription, and inducing apoptosis in rapidly dividing tumor cells. Oxaltero 100mg Injection is primarily indicated for the treatment of colorectal cancer, including adjuvant therapy and metastatic settings, commonly administered in combination regimens such as FOLFOX.

Oxaltero 100mg Injection is manufactured under stringent GMP and injectable quality standards to ensure consistent potency, safety, and stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Oxyin 50mg Injection
Composition: Oxaliplatin Injection 50mg
International Trade Name: Eloxatin®

Oxyin 50 is a high-quality Oxaliplatin 50mg Injection, a bioequivalent formulation of the internationally recognized platinum-based anticancer agent marketed under the brand name Eloxatin®. Manufactured in WHO-GMP certified facilities, Oxyin Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in colorectal and gastrointestinal cancers.

Oxaliplatin is a third-generation platinum compound that exerts cytotoxic activity by forming DNA cross-links, thereby inhibiting DNA replication and transcription and inducing apoptosis in rapidly dividing tumor cells. Oxyin 50mg Injection is primarily indicated for the treatment of colorectal cancer, including adjuvant therapy and metastatic settings, commonly administered in combination regimens such as FOLFOX.

Oxyin 50mg Injection is manufactured under stringent GMP and injectable quality standards to ensure consistent potency, safety, and stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Oxaliptin 50mg Injection
Composition: Oxaliplatin Injection 50mg
International Trade Name: Eloxatin®

Oxaliptin 50 is a high-quality Oxaliplatin 50mg Injection, a bioequivalent formulation of the internationally recognized platinum-based anticancer agent marketed under the brand name Eloxatin®. Manufactured in WHO-GMP certified facilities, Oxaliptin Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in colorectal and gastrointestinal cancers.

Oxaliplatin is a third-generation platinum compound that exerts cytotoxic activity by forming DNA cross-links, thereby inhibiting DNA replication and transcription and inducing apoptosis in rapidly dividing tumor cells. Oxaliptin 50mg Injection is primarily indicated for the treatment of colorectal cancer, including adjuvant therapy and metastatic settings, commonly administered in combination regimens such as FOLFOX.

Oxaliptin 50mg Injection is manufactured under stringent GMP and injectable quality standards to ensure consistent potency, safety, and stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Celdach 100mg Injection
Composition: Oxaliplatin Injection 100mg
International Trade Name: Eloxatin®

Celdach 100 is a high-quality Oxaliplatin 100mg Injection, a bioequivalent formulation of the internationally recognized platinum-based anticancer agent marketed under the brand name Eloxatin®. Manufactured in WHO-GMP certified facilities, Celdach Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in colorectal and gastrointestinal cancers.

Oxaliplatin is a third-generation platinum compound that exerts cytotoxic activity by forming DNA cross-links, inhibiting DNA replication and transcription, and inducing apoptosis in rapidly dividing tumor cells. Celdach 100mg Injection is primarily indicated for the treatment of colorectal cancer, including adjuvant therapy and metastatic settings, commonly administered in combination regimens such as FOLFOX.

Celdach 100mg Injection is manufactured under stringent GMP and injectable quality standards to ensure consistent potency, safety, and stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Oxazer 100mg Injection
Composition: Oxaliplatin Injection 100mg
International Trade Name: Eloxatin®

Oxazer 100 is a high-quality Oxaliplatin 100mg Injection, a bioequivalent formulation of the internationally recognized platinum-based anticancer agent marketed under the brand name Eloxatin®. Manufactured in WHO-GMP certified facilities, Oxazer Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in colorectal and gastrointestinal cancers.

Oxaliplatin is a third-generation platinum compound that exerts cytotoxic activity by forming DNA cross-links, inhibiting DNA replication and transcription, and inducing apoptosis in rapidly dividing tumor cells. Oxazer 100mg Injection is primarily indicated for the treatment of colorectal cancer, including adjuvant therapy and metastatic settings, commonly administered in combination regimens such as FOLFOX.

Oxazer 100mg Injection is manufactured under stringent GMP and injectable quality standards to ensure consistent potency, safety, and stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Oxalieva 100mg Injection
Composition: Oxaliplatin Injection 100mg
International Trade Name: Eloxatin®

Oxalieva 100 is a high-quality Oxaliplatin 100mg Injection, a bioequivalent formulation of the internationally recognized platinum-based anticancer agent marketed under the brand name Eloxatin®. Manufactured in WHO-GMP certified facilities, Oxalieva Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in colorectal and gastrointestinal cancers.

Oxaliplatin is a third-generation platinum compound that exerts cytotoxic activity by forming DNA cross-links, inhibiting DNA replication and transcription, and inducing apoptosis in rapidly dividing tumor cells. Oxalieva 100mg Injection is primarily indicated for the treatment of colorectal cancer, including adjuvant therapy and metastatic settings, commonly administered in combination regimens such as FOLFOX.

Oxalieva 100mg Injection is manufactured under stringent GMP and injectable quality standards to ensure consistent potency, safety, and stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Oxaliptin 100mg Injection
Composition: Oxaliplatin Injection 100mg
International Trade Name: Eloxatin®

Oxaliptin 100 is a high-quality Oxaliplatin 100mg Injection, a bioequivalent formulation of the internationally recognized platinum-based anticancer agent marketed under the brand name Eloxatin®. Manufactured in WHO-GMP certified facilities, Oxaliptin Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in colorectal and gastrointestinal cancers.

Oxaliplatin is a third-generation platinum compound that exerts cytotoxic activity by forming DNA cross-links, inhibiting DNA replication and transcription, and inducing apoptosis in rapidly dividing tumor cells. Oxaliptin 100mg Injection is primarily indicated for the treatment of colorectal cancer, including adjuvant therapy and metastatic settings, commonly administered in combination regimens such as FOLFOX.

Oxaliptin 100mg Injection is manufactured under stringent GMP and injectable quality standards to ensure consistent potency, safety, and stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Erbitux 5mg/mL Injection
Composition: Cetuximab Injection 5mg/mL
International Trade Name: Erbitux®

Erbitux 5 is a high-quality Cetuximab 5mg/mL Injection, a bioequivalent formulation of the internationally recognized monoclonal antibody marketed under the brand name Erbitux®. Manufactured in WHO-GMP certified facilities, Erbitux Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in colorectal and head & neck cancers.

Cetuximab is a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR), inhibiting EGFR-mediated cell proliferation, angiogenesis, and survival. Erbitux 5mg/mL Injection is primarily indicated for the treatment of metastatic colorectal cancer in combination with chemotherapy, and for locally advanced squamous cell carcinoma of the head and neck.

Erbitux 5mg/mL Injection is manufactured under stringent GMP and biologics quality standards to ensure consistent efficacy, safety, and stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Lupitux 100mg Injection
Composition: Cetuximab Injection 100mg
International Trade Name: Erbitux®

Lupitux 100 is a high-quality Cetuximab 100mg Injection, a bioequivalent formulation of the internationally recognized monoclonal antibody marketed under the brand name Erbitux®. Manufactured in WHO-GMP certified facilities, Lupitux Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in colorectal and head & neck cancers.

Cetuximab is a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR), inhibiting EGFR-mediated cell proliferation, angiogenesis, and survival. Lupitux 100mg Injection is primarily indicated for the treatment of metastatic colorectal cancer in combination with chemotherapy and for locally advanced squamous cell carcinoma of the head and neck.

Lupitux 100mg Injection is manufactured under stringent GMP and biologics quality standards to ensure consistent efficacy, safety, and stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Cetuxa 100mg Injection
Composition: Cetuximab Injection 100mg
International Trade Name: Erbitux®

Cetuxa 100 is a high-quality Cetuximab 100mg Injection, a bioequivalent formulation of the internationally recognized monoclonal antibody marketed under the brand name Erbitux®. Manufactured in WHO-GMP certified facilities, Cetuxa Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in colorectal and head & neck cancers.

Cetuximab is a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR), inhibiting EGFR-mediated cell proliferation, angiogenesis, and tumor survival. Cetuxa 100mg Injection is primarily indicated for the treatment of metastatic colorectal cancer in combination with chemotherapy and for locally advanced squamous cell carcinoma of the head and neck.

Cetuxa 100mg Injection is manufactured under stringent GMP and biologics quality standards to ensure consistent efficacy, safety, and stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Leuget 50mg Injection
Composition: Leucovorin Calcium 50mg Injection IP
International Trade Name: Wellcovorin®

Leuget 50 is a high-quality Leucovorin Calcium 50mg Injection, a bioequivalent formulation of the internationally recognized folinic acid therapy marketed under the brand name Wellcovorin®. Manufactured in WHO-GMP certified facilities, Leuget Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs and supportive care regimens.

Leucovorin Calcium is a reduced form of folic acid that enhances the therapeutic effect of fluoropyrimidine-based chemotherapies (such as 5-Fluorouracil) and is used to rescue normal cells from high-dose methotrexate toxicity. Leuget 50mg Injection is primarily indicated as an adjuvant therapy in colorectal cancer, for methotrexate rescue, and in combination regimens to improve the efficacy of chemotherapeutic protocols.

Leuget 50mg Injection is manufactured under stringent GMP and injectable quality standards to ensure consistent potency, safety, and stability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Intensic 100mg Injection
Composition: Irinotecan Injection 100mg (20mg/mL)
International Trade Name: Campto®

Intensic 100 is a high-quality Irinotecan 100mg Injection, a bioequivalent formulation of the internationally recognized topoisomerase I inhibitor marketed under the brand name Campto®. Manufactured in WHO-GMP certified facilities, Intensic Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in colorectal and other gastrointestinal cancers.

Irinotecan is a semisynthetic derivative of camptothecin that inhibits topoisomerase I, preventing DNA replication and transcription, leading to apoptosis of rapidly dividing tumor cells. Intensic 100mg Injection is primarily indicated for the treatment of metastatic colorectal cancer, both as first-line therapy in combination regimens (e.g., FOLFIRI) and in patients who have progressed following fluoropyrimidine-based therapy.

Intensic 100mg Injection is manufactured under stringent GMP and injectable quality standards to ensure consistent potency, safety, and stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Tipanat Capsule
Composition: Trifluridine 20mg + Tipiracil 8.19mg
International Trade Name: Lonsurf®

Tipanat is a high-quality combination oral anticancer capsule containing Trifluridine and Tipiracil, a bioequivalent formulation of the internationally recognized product marketed under the brand name Lonsurf®. Manufactured in WHO-GMP certified facilities, Tipanat Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in metastatic colorectal cancer.

Trifluridine is a nucleoside analogue that incorporates into DNA, disrupting DNA synthesis and tumor cell proliferation. Tipiracil inhibits the degradation of trifluridine, enhancing its bioavailability and anticancer activity. Tipanat Capsules are primarily indicated for the treatment of metastatic colorectal cancer and metastatic gastric cancer in patients who have been previously treated with standard therapies.

Tipanat Capsules are manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent efficacy, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, infusion centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

OXALYRA 50mg Injection
Composition: Oxaliplatin Injection USP 50mg
International Trade Name: Eloxatin®

OXALYRA 50 is a high-quality Oxaliplatin 50mg Injection, a bioequivalent formulation of the internationally recognized platinum-based anticancer agent marketed under the brand name Eloxatin®. Manufactured in WHO-GMP certified facilities, OXALYRA Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in colorectal and gastrointestinal cancers.

Oxaliplatin is a third-generation platinum compound that exerts cytotoxic activity by forming DNA cross-links, inhibiting DNA replication and transcription, and inducing apoptosis in rapidly dividing tumor cells. OXALYRA 50mg Injection is primarily indicated for the treatment of colorectal cancer, including adjuvant therapy and metastatic settings, commonly administered in combination regimens such as FOLFOX.

OXALYRA 50mg Injection is manufactured under stringent GMP and injectable quality standards to ensure consistent potency, safety, and stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.